Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metas… (NCT06784947) | Clinical Trial Compass
Active — Not RecruitingPhase 2
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
United States13 participantsStarted 2025-03-25
Plain-language summary
The goal of this study is to learn if a new combination treatment is effective for patients with microsatellite stable, advanced colorectal cancer. The study treatment combines 3 drugs: atezolizumab, bevacizumab, and tiragolumab. The main questions the study aims to answer are:
1. Does the study treatment effectively treat colorectal cancer?
2. Is the study treatment safe for patients with colorectal cancer?
3. How does the study treatment effect the immune system in patients with colorectal cancer?
Participants in this study will receive the study treatment and undergo checkups, laboratory tests, and imaging tests for monitoring. Some participants will also undergo tumor biopsies.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Able to sign the consent form.
✓. Stated willingness and ability to comply with all study procedures and be available for the duration of the study.
✓. ≥ 18 years at the time of informed consent.
✓. Measurable disease (disease that can be viewed and measured on scans), as assessed by the investigator per RECIST v1.1.
✓. If in Cohort A, (1) the patient must state willingness to undergo pre- and on-treatment biopsies, and (2) the patient's disease must be amenable to biopsy.
✓. Eastern Cooperative Oncology Group performance status of 0-2.
✕. Known microsatellite instability-high or deficient mismatch repair status, or unknown status for both MSI and MMR.
✕. Prior testing documenting a BRAF V600E mutation, or unknown testing results for KRAS, NRAS, and BRAF.
✕. A limited number of patients with active liver metastases will be permitted in this trial. Those with a history of definitively treated liver metastases with treatment occurring at least 6 months prior to enrollment with no evidence of metastatic disease in the liver on subsequent imaging may be eligible to enroll as a patient without active liver disease.
✕. Known symptomatic, untreated, or actively progressing central nervous system metastases. Asymptomatic patients with treated CNS lesions are eligible, provided that additional criteria are met.
✕. History of leptomeningeal disease or carcinomatous meningitis.
✕. Spinal cord compression not definitively treated with surgery and/or radiation.
✕. Uncontrolled tumor-related pain. Patients requiring pain medication must be on a stable regimen at study entry.